FGF21 and metabolic dysfunction-associated steatotic liver disease: In the univariate meta-regression analysis, the percentage of patients with T2DM was positively associated with FGF-21 SMD between patients with NAFLD and controls and could explain 49.2% of the heterogeneity among studies (Table 5; Fig. S5).